

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM841020

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Dicerna Pharmaceuticals, Inc.		09/19/2023	Corporation:
RECEIVING PARTY DATA			
Name:	Novo Nordisk Health Care AG		
Street Address:	The Circle 32/38		
City:	Zürich		
State/Country:	SWITZERLAND		
Postal Code:	CH-8058		
Entity Type:	Aktiengesellschaft (Ag): SWITZERLAND		
PROPERTY NUMBERS Total: 2			
Property Type	Number	Word Mark	
Serial Number:	90191150	RIVFLOZA	
Serial Number:	90191155	RENZIGA	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Email:	trademarkdocket@whitecase.com		
Correspondent Name:	Spencer Beall		
Address Line 1:	1221 Avenue of the Americas		
Address Line 2:	Trademark Department		
Address Line 4:	New York, NEW YORK 10020		
ATTORNEY DOCKET NUMBER:	1123029-0335		
NAME OF SUBMITTER:	Spencer Beall		
SIGNATURE:	/Spencer Beall/		
DATE SIGNED:	09/21/2023		
Total Attachments: 5			
source=Trademark Assignment - signed#page1.tif			
source=Trademark Assignment - signed#page2.tif			
source=Trademark Assignment - signed#page3.tif			
source=Trademark Assignment - signed#page4.tif			

CH \$65.00 90191150

Dated September /__ / 2023

U.S. Trademark Assignment

between

DICERNA PHARMACEUTICALS, INC.

Assignor

AND

NOVO NORDISK HEALTH CARE AG

Assignee

9/6/2023 10:11
[Trademark Assignment (Novo Nordisk Health Care AG - Dicerna) (To
Sign and Date).docx]

TRADEMARK
REEL: 008202 FRAME: 0227

This Agreement is dated September 12, 2023 by and between Dicerna Pharmaceuticals, Inc., a Delaware corporation with an address at 75 Hayden Avenue, Lexington, MA 02421 ("Dicerna" or "Assignor") and Novo Nordisk Health Care AG, a Swiss Aktiengesellschaft with an address at The Circle 32/38, CH-8058 Zürich, Switzerland ("NN" or "Assignee"), each a Party and collectively the Parties.

WHEREAS, Dicerna owns the trademark applications listed in Schedule A, together with all unregistered rights in the trademarks (collectively, the "Trademarks").

WHEREAS, pursuant to the Asset Transfer Agreement dated December 28, 2021, NN, acquired Dicerna and all of its corporate assets, including all intellectual property rights and related assets.

WHEREAS, Dicerna wishes to assign the Trademarks to NN as Dicerna's successor.

NOW, THEREFORE, IT IS AGREED THAT:

1. Pursuant to and for the consideration set out in Article 2 of the Asset Transfer Agreement, Dicerna hereby assigns to Novo Nordisk Health Care AG its right, title, and interest in and to the Trademarks, effective as of the signature date of this Agreement (the "Effective Date").
2. This Agreement includes all rights and benefits relating to the Trademarks, including (without limitation) any right that Dicerna may have to bring action or claim relief in respect to any infringement of the Trademarks, whether occurring on or before the Effective Date.
3. Dicerna agrees to sign any documents and take all additional action necessary (if any) to give effect to this Agreement and effectuate the assignment of the Trademarks at NN's request, including to enable NN to fulfill all trademark assignment and assignment recordal requirements of the United States Patent & Trademark Office and/or any other relevant authorities.
4. This Agreement and any issues, disputes, or claims arising out of or in connection with it (whether contractual or non-contractual in nature) shall be governed by and construed in accordance with the laws of Switzerland. Each Party submits to the exclusive jurisdiction of the Swiss courts which may arise under or in connection with this Agreement.
5. This Agreement, and all of its provisions, will be binding upon and inure to the benefit of the parties and their respective officers, directors, employees, agents, predecessors, successors, purchasers, transferees, assigns, parents, affiliates, subsidiaries, related companies, and/or others in privity with them.
6. Each Party warrants and represents that the person signing this Agreement has full power and actual authority to enter into this Agreement and to bind the Parties' respective officers, shareholders, employees, agents, predecessors, successors, purchasers, transferees, assigns, parents, affiliates, subsidiaries, related companies, and/or others in privity with them.
7. This Agreement is signed voluntarily and without any duress or undue influence on Dicerna or its officers, employees, agents or attorneys, and no Party is relying on any inducements, promises, statements, or representations made by any other Party or any of its officers, employees, agents or attorneys other than as expressly set forth in this Agreement.
8. This Agreement constitutes the entire agreement and understanding between the Parties and supersedes any prior agreements, negotiations, or understanding between or among them relating to the subject matter of this Agreement. If any portion of this Agreement is declared invalid or unenforceable for any reason, the remainder of this Agreement will be deemed and remain fully valid and enforceable.

9. This Agreement may be signed using one or more counterparts, each of which signed (including via electronic signature) will be deemed to be an original and all of which when taken together will constitute one and the same agreement.

DICERNA PHARMACEUTICALS, INC

By: 

Title: Head of IP& Legal - US R&D

Date: September 19, 2023

NOVO NORDISK HEALTH CARE AG

By: 

Title: Authorized Signatory

Date: September 12, 2023

SCHEDULE A

Mark	Application No.	Filing Date	Basis	Goods/Services	Name
RIVFLOZA	90/191,150	September 18, 2020	1(b) -- intent to use	<p><u>Class 5</u>: Pharmaceutical preparations for the treatment of various diseases, namely, pharmaceutical preparations for the treatment of rare diseases in the nature of genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; drug delivery agents in the nature of oligonucleotide compounds for use in the targeted delivery of RNAi therapy; chemical compounds that act as a platform for the delivery of drugs in the nature of drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals</p> <p><u>Class 42</u>: Scientific research and development of pharmaceutical preparations, compounds for use in the targeted delivery of therapy, chemical compounds that act as a platform for the delivery of drugs, and drug delivery agents; scientific research and development; scientific investigations for medical purposes; providing medical and scientific research information in the field of pharmaceuticals and clinical trials</p>	Dicerna Pharmaceuticals, Inc.
RENZIGA	90191155	September 18, 2020	1(b) -- intent to use	<p><u>Class 5</u>: Pharmaceutical preparations for the treatment of various diseases, namely, pharmaceutical preparations for the treatment of rare diseases in the nature of genetic disorders, chronic liver diseases,</p>	Dicerna Pharmaceuticals, Inc.

			<p>cardiovascular diseases, cancers, and viral infections; drug delivery agents in the nature of oligonucleotide compounds for use in the targeted delivery of RNAi therapy; chemical compounds that act as a platform for the delivery of drugs in the nature of drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals.</p> <p><u>Class 42:</u> Scientific research and development of pharmaceutical preparations, compounds for use in the targeted delivery of therapy, chemical compounds that act as a platform for the delivery of drugs, and drug delivery agents; scientific research and development; scientific investigations for medical purposes; providing medical and scientific research information in the field of pharmaceuticals and clinical trials.</p>	
--	--	--	---	--